Isoray Press Release Archive

In 2023 Isoray merged with Viewpoint Molecular Targeting. Access the archived Press Releases from Isoray.

Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

The result from first patient dosed with 212Pb-VMT-α-NET in India on a compassionate use basis showed favorable responses after the first dose.
The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated encouraging results after a single low dose of 212Pb-VMT-α-NET.

Read More

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

“The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company’s core brachytherapy business lack of orders from our largest customer and post-COVID recovery efforts resulted in a sales decline.

Read More

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

New tagline: “Treating cancers from the inside out”
New corporate website https://www.perspectivetherapeutics.com
New NYSE American stock ticker symbol to be CATX, effective February 21, 2023…..

Read More
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

Outgoing Isoray CEO Lori Woods said, “This merger represents an important milestone for Isoray. The merger with Viewpoint Molecular Targeting demonstrates our commitment to build on our shared belief of treating cancers from the inside out while providing personalized targeted treatment options for cancer patients…

Read More
Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 shares….

Read More
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023

The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1…..

Read More
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

The Board of Directors, as well as leading proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co., recommend stockholders vote in support of Proposal 1.

Read More
Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. “The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders….

Read More
Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002.

Read More
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

The presentation will provide an overview of Viewpoint’s pipeline along with a review of data presented at this year’s European Association of Nuclear Medicine conference which concludes on October 19 in Barcelona, Spain.

Read More
Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint becoming a wholly owned subsidiary of Isoray.

Read More
Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

To listen to the conference call, please dial 888-506-0062. For callers outside the U.S., please dial 973-528-0011.

Read More

Want to keep up-to-date on news and information?

Sign up
Scroll to top